Daniel Starczynowski
Overview
Explore the profile of Daniel Starczynowski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
51
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gorak E, Otterstatter M, Baghdadi T, Gillis N, Foran J, Liu J, et al.
Blood Adv
. 2023 Aug;
7(20):6120-6129.
PMID: 37552083
Myelodysplastic neoplasms (MDS) are a collection of hematopoietic disorders with widely variable prognoses and treatment options. Accurate pathologic diagnoses present challenges because of interobserver variability in interpreting morphology and quantifying...
2.
Marion W, Koppe T, Chen C, Wang D, Frenis K, Fierstein S, et al.
Leukemia
. 2023 Jun;
37(8):1698-1708.
PMID: 37391485
Many inherited bone marrow failure syndromes (IBMFSs) present a high risk of transformation to myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). During transformation of IBMFSs, hematopoietic stem and progenitor...
3.
Stahl M, Abdel-Wahab O, Wei A, Savona M, Xu M, Xie Z, et al.
Blood Adv
. 2022 Oct;
7(12):2709-2714.
PMID: 36260702
No abstract available.
4.
Zhang Y, Chen X, Wang H, Gordon-Mitchell S, Sahu S, Bhagat T, et al.
J Hematol Oncol
. 2022 Jul;
15(1):100.
PMID: 35883108
No abstract available.
5.
Zhang Y, Chen X, Wang H, Gordon-Mitchell S, Sahu S, Bhagat T, et al.
J Hematol Oncol
. 2022 May;
15(1):70.
PMID: 35606824
Advanced pancreatic ductal adenocarcinoma (PDAC) is usually an incurable malignancy that needs newer therapeutic targets. Interleukin-1 receptor accessory protein (IL1RAP) is an innate immune mediator that regulates activation of pro-inflammatory...
6.
Azhar M, Kincaid Z, Kesarwani M, Ahmed A, Wunderlich M, Latif T, et al.
Blood Adv
. 2021 Nov;
6(4):1186-1192.
PMID: 34768286
Despite the introduction of more selective FLT3 inhibitors to treat FLT3-mutated acute myeloid leukemia (AML), remissions are short lived, and patients show progressive disease after an initial response. Acquisition of...
7.
Gilmore T, Kalaitzidis D, Starczynowski D
Cancer Lett
. 2002 Nov;
181(1):1-9.
PMID: 12430173
The Rel/NF-kappa B family is a group of structurally-related, tightly-regulated transcription factors that control the expression of a multitude of genes involved in key cellular and organismal processes. The Rel/NF-kappa...